Cancer Therapy AdvisorLung Cancer: FDA Collaboration Highlights Real-world Immunotherapy Treatment PatternsCancer Therapy Advisor… other minority (8.5%) patients, and 13.2% were of unknown race/ethnicity. Just 8.3% of patients were tested for PD-L1 e… Continue reading
Cancer Therapy AdvisorLung Cancer: FDA Collaboration Highlights Real-world Immunotherapy Treatment PatternsCancer Therapy Advisor… other minority (8.5%) patients, and 13.2% were of unknown race/ethnicity. Just 8.3% of patients were tested for PD-L1 e… Continue reading
Phys.Org |
Synthetic virus to tackle antimicrobial resistance
Phys.Org NPL is addressing technology and innovation challenges in response to this, including support for the implementation of synthetic/engineering biology. In line with NPL’s approach to addressing the global threat of antimicrobial resistance by helping to … |
BioPharma-Reporter.com |
Paragon expansion to address ‘deficit in gene therapy CDMO capacity’
BioPharma-Reporter.com Paragon Bioservices’ facility in Baltimore, US will make clinical batches of gene therapies for customers by the fourth quarter 2014, with commercial manufacturing capabilities offered in the next two years. According to CEO Pete Buzy, “the growing … |